Piramal Pharma Solutions (PPS), a global Contract Development and Manufacturing Organization (CDMO) under Piramal Pharma Ltd., and NewAmsterdam Pharma Company N.V. have announced the inauguration of a new oral solid dosage (OSD) suite at Piramal’s Sellersville, Pennsylvania facility. The site, already a hub for advanced drug product development and manufacturing, now features a state-of-the-art suite dedicated to fixed dose combination (FDC) products, designed to support advanced capabilities in granulation, compression, tableting, and coating.
The multi-million-dollar investment includes significant equipment upgrades and reconfigured space to streamline production. The facility will play a critical role in manufacturing NewAmsterdam Pharma’s investigational non-statin cholesterol therapy aimed at reducing LDL-C, pending regulatory approval.
Beyond Sellersville, Piramal Pharma Solutions’ global network has contributed to the program, with the Ahmedabad PPDS site in India supporting product development and the Pithampur, India site providing dual sourcing capabilities.
“We are thrilled to expand our OSD production capabilities at Sellersville with this new suite,” said Peter DeYoung, CEO, Piramal Global Pharma. “This reinforces both our capacity expansion and our patient-centric approach.”
Douglas Kling, COO of NewAmsterdam Pharma, added, “By investing in Piramal’s Sellersville facility, we are ensuring high-precision, efficient manufacturing to meet future demand. This collaboration represents an important step in bringing our therapy to patients worldwide.”
The investment will also generate over 20 new jobs in the next five years, boosting local employment and the economy. Both companies emphasized that the suite reflects their shared focus on innovation, efficiency, and patient access, helping accelerate delivery of the therapy to those in need.